STOCK TITAN

[8-K] Castle Biosciences, Inc. Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary

Business First Bancshares, Inc. (BFST) has submitted a Form 144 notice covering a planned sale of 5,164 common shares via Morgan Stanley Smith Barney on or about 04 Aug 2025. The stock originated from six restricted-stock grants received between 2021-2025. At the filing’s stated aggregate market value of $119,186, the implied sale price is roughly $23.07 per share.

The block equals just 0.017 % of the company’s 29.7 million shares outstanding, indicating negligible dilution or ownership impact. No other insider sales were reported in the preceding three months, and the filer certifies awareness of no undisclosed material information. The document contains no operational or financial performance data and does not identify the seller’s remaining stake.

Business First Bancshares, Inc. (BFST) ha presentato un avviso Form 144 riguardante una prevista vendita di 5.164 azioni ordinarie tramite Morgan Stanley Smith Barney intorno al 04 agosto 2025. Le azioni provengono da sei assegnazioni di azioni vincolate ricevute tra il 2021 e il 2025. Con un valore di mercato aggregato dichiarato di 119.186 $, il prezzo di vendita implicito è di circa 23,07 $ per azione.

Il blocco rappresenta solo lo 0,017 % delle 29,7 milioni di azioni in circolazione della società, indicando un impatto trascurabile su diluizione o proprietà. Non sono state segnalate altre vendite da parte di insider nei tre mesi precedenti, e chi presenta la dichiarazione certifica di non essere a conoscenza di informazioni materiali non divulgate. Il documento non contiene dati operativi o finanziari e non indica la quota residua del venditore.

Business First Bancshares, Inc. (BFST) ha presentado un aviso Formulario 144 para una venta planificada de 5,164 acciones comunes a través de Morgan Stanley Smith Barney alrededor del 04 de agosto de 2025. Las acciones provienen de seis concesiones de acciones restringidas recibidas entre 2021 y 2025. Con un valor de mercado agregado declarado de 119,186 $, el precio de venta implícito es aproximadamente 23.07 $ por acción.

El bloque equivale a solo el 0.017 % de las 29.7 millones de acciones en circulación de la empresa, lo que indica un impacto insignificante en la dilución o propiedad. No se reportaron otras ventas internas en los tres meses anteriores, y quien presenta el aviso certifica no tener conocimiento de información material no divulgada. El documento no contiene datos operativos ni financieros y no identifica la participación restante del vendedor.

Business First Bancshares, Inc. (BFST)는 2025년 8월 4일경 Morgan Stanley Smith Barney를 통해 5,164주 보통주 매각 계획에 관한 Form 144 신고서를 제출했습니다. 해당 주식은 2021년부터 2025년 사이에 받은 여섯 건의 제한 주식 부여에서 기인합니다. 신고서에 명시된 총 시장 가치 119,186달러를 기준으로, 주당 매각 예상 가격은 약 23.07달러입니다.

이 매각 주식은 회사의 2,970만 주 발행 주식 중 단지 0.017%에 해당하여 희석이나 소유권에 미치는 영향이 거의 없습니다. 지난 3개월간 다른 내부자 매각 보고는 없었으며, 신고자는 미공개 중요 정보가 없음을 인증했습니다. 문서에는 영업 또는 재무 성과 데이터가 포함되어 있지 않으며, 판매자의 잔여 지분도 명시하지 않았습니다.

Business First Bancshares, Inc. (BFST) a déposé un avis Formulaire 144 concernant une vente prévue de 5 164 actions ordinaires via Morgan Stanley Smith Barney aux alentours du 04 août 2025. Les actions proviennent de six attributions d’actions restreintes reçues entre 2021 et 2025. Avec une valeur marchande totale déclarée de 119 186 $, le prix de vente implicite est d’environ 23,07 $ par action.

Le bloc représente seulement 0,017 % des 29,7 millions d’actions en circulation de la société, indiquant un impact négligeable sur la dilution ou la propriété. Aucune autre vente d’initiés n’a été signalée au cours des trois mois précédents, et le déposant certifie ne pas avoir connaissance d’informations matérielles non divulguées. Le document ne contient aucune donnée opérationnelle ou financière et n’identifie pas la participation restante du vendeur.

Business First Bancshares, Inc. (BFST) hat eine Form 144-Meldung eingereicht, die einen geplanten Verkauf von 5.164 Stammaktien über Morgan Stanley Smith Barney etwa am 04. August 2025 betrifft. Die Aktien stammen aus sechs Restricted-Stock-Zuteilungen, die zwischen 2021 und 2025 erhalten wurden. Bei einem angegebenen gesamten Marktwert von 119.186 $ ergibt sich ein impliziter Verkaufspreis von etwa 23,07 $ pro Aktie.

Das Volumen entspricht lediglich 0,017 % der 29,7 Millionen ausstehenden Aktien des Unternehmens, was auf eine vernachlässigbare Verwässerung oder Eigentumsauswirkung hinweist. In den vorangegangenen drei Monaten wurden keine weiteren Insiderverkäufe gemeldet, und der Melder bestätigt, keine nicht offengelegten wesentlichen Informationen zu kennen. Das Dokument enthält keine operativen oder finanziellen Leistungsdaten und nennt nicht den verbleibenden Anteil des Verkäufers.

Positive
  • None.
Negative
  • Insider intends to sell shares, which can be perceived negatively for sentiment even though the amount is immaterial.

Insights

TL;DR: Small insider sale (0.017 % float)—immaterial to BFST fundamentals; sentiment slightly negative but overall neutral impact.

The Form 144 discloses an intended sale worth roughly $119k. Scale is de-minimis relative to BFST’s market capitalization, so it should not alter valuation metrics or liquidity. Still, insider selling—especially of recently vested restricted stock—can be interpreted as modestly bearish on near-term price. Absence of other sales and the Rule 144 attestation reduce concern. Overall, I view this as a routine, non-material filing.

TL;DR: Filing meets compliance; sale volume trivial; governance risk minimal.

The notice follows proper Rule 144 procedures, providing full acquisition history and broker details. Seller’s representation of no undisclosed adverse information mitigates governance worries. Because the shares stem from equity compensation and the stake is tiny, I classify the event as standard insider liquidity rather than a strategic exit. Investors should monitor future filings for pattern shifts, but this single action is not impactful.

Business First Bancshares, Inc. (BFST) ha presentato un avviso Form 144 riguardante una prevista vendita di 5.164 azioni ordinarie tramite Morgan Stanley Smith Barney intorno al 04 agosto 2025. Le azioni provengono da sei assegnazioni di azioni vincolate ricevute tra il 2021 e il 2025. Con un valore di mercato aggregato dichiarato di 119.186 $, il prezzo di vendita implicito è di circa 23,07 $ per azione.

Il blocco rappresenta solo lo 0,017 % delle 29,7 milioni di azioni in circolazione della società, indicando un impatto trascurabile su diluizione o proprietà. Non sono state segnalate altre vendite da parte di insider nei tre mesi precedenti, e chi presenta la dichiarazione certifica di non essere a conoscenza di informazioni materiali non divulgate. Il documento non contiene dati operativi o finanziari e non indica la quota residua del venditore.

Business First Bancshares, Inc. (BFST) ha presentado un aviso Formulario 144 para una venta planificada de 5,164 acciones comunes a través de Morgan Stanley Smith Barney alrededor del 04 de agosto de 2025. Las acciones provienen de seis concesiones de acciones restringidas recibidas entre 2021 y 2025. Con un valor de mercado agregado declarado de 119,186 $, el precio de venta implícito es aproximadamente 23.07 $ por acción.

El bloque equivale a solo el 0.017 % de las 29.7 millones de acciones en circulación de la empresa, lo que indica un impacto insignificante en la dilución o propiedad. No se reportaron otras ventas internas en los tres meses anteriores, y quien presenta el aviso certifica no tener conocimiento de información material no divulgada. El documento no contiene datos operativos ni financieros y no identifica la participación restante del vendedor.

Business First Bancshares, Inc. (BFST)는 2025년 8월 4일경 Morgan Stanley Smith Barney를 통해 5,164주 보통주 매각 계획에 관한 Form 144 신고서를 제출했습니다. 해당 주식은 2021년부터 2025년 사이에 받은 여섯 건의 제한 주식 부여에서 기인합니다. 신고서에 명시된 총 시장 가치 119,186달러를 기준으로, 주당 매각 예상 가격은 약 23.07달러입니다.

이 매각 주식은 회사의 2,970만 주 발행 주식 중 단지 0.017%에 해당하여 희석이나 소유권에 미치는 영향이 거의 없습니다. 지난 3개월간 다른 내부자 매각 보고는 없었으며, 신고자는 미공개 중요 정보가 없음을 인증했습니다. 문서에는 영업 또는 재무 성과 데이터가 포함되어 있지 않으며, 판매자의 잔여 지분도 명시하지 않았습니다.

Business First Bancshares, Inc. (BFST) a déposé un avis Formulaire 144 concernant une vente prévue de 5 164 actions ordinaires via Morgan Stanley Smith Barney aux alentours du 04 août 2025. Les actions proviennent de six attributions d’actions restreintes reçues entre 2021 et 2025. Avec une valeur marchande totale déclarée de 119 186 $, le prix de vente implicite est d’environ 23,07 $ par action.

Le bloc représente seulement 0,017 % des 29,7 millions d’actions en circulation de la société, indiquant un impact négligeable sur la dilution ou la propriété. Aucune autre vente d’initiés n’a été signalée au cours des trois mois précédents, et le déposant certifie ne pas avoir connaissance d’informations matérielles non divulguées. Le document ne contient aucune donnée opérationnelle ou financière et n’identifie pas la participation restante du vendeur.

Business First Bancshares, Inc. (BFST) hat eine Form 144-Meldung eingereicht, die einen geplanten Verkauf von 5.164 Stammaktien über Morgan Stanley Smith Barney etwa am 04. August 2025 betrifft. Die Aktien stammen aus sechs Restricted-Stock-Zuteilungen, die zwischen 2021 und 2025 erhalten wurden. Bei einem angegebenen gesamten Marktwert von 119.186 $ ergibt sich ein impliziter Verkaufspreis von etwa 23,07 $ pro Aktie.

Das Volumen entspricht lediglich 0,017 % der 29,7 Millionen ausstehenden Aktien des Unternehmens, was auf eine vernachlässigbare Verwässerung oder Eigentumsauswirkung hinweist. In den vorangegangenen drei Monaten wurden keine weiteren Insiderverkäufe gemeldet, und der Melder bestätigt, keine nicht offengelegten wesentlichen Informationen zu kennen. Das Dokument enthält keine operativen oder finanziellen Leistungsdaten und nennt nicht den verbleibenden Anteil des Verkäufers.

0001447362FALSE00014473622025-08-042025-08-04

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 4, 2025

Castle Biosciences, Inc.
(Exact name of registrant as specified in its charter)
     
Delaware 001-38984 77-0701774
(state or other jurisdiction
of incorporation)
 (Commission
File Number)
 (I.R.S. Employer
Identification No.)
505 S. Friendswood Drive, Suite 401
Friendswood, Texas
77546
(Address of principal executive offices)(Zip Code)

Registrant’s telephone number, including area code: (866) 788-9007

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: 

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) 
    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) 
    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) 
 
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s) Name of each exchange on which registered
Common Stock, $0.001 par value per shareCSTL The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b–2 of the Securities Exchange Act of 1934 (§ 240.12b–2 of this chapter).
Emerging growth company  
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ 



Item 2.02    Results of Operations and Financial Condition.

On August 4, 2025, Castle Biosciences, Inc. (the “Company”) issued a press release announcing its financial results for the second quarter ended June 30, 2025. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.

The information contained or incorporated in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference into any filing under the Exchange Act or the Securities Act of 1933, as amended (the “Securities Act”), except as expressly set forth by specific reference in such filing to this Current Report on Form 8-K.

Item 7.01    Regulation FD Disclosure.

On August 4, 2025, the Company made available the slide presentation attached hereto as Exhibit 99.2. Information from this slide presentation may also be used by the management of the Company in future meetings regarding the Company.

The information contained or incorporated in this Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.2, shall not be deemed “filed” for purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference into any filing under the Exchange Act or the Securities Act except as expressly set forth by specific reference in such filing to this Current Report on Form 8-K.

Item 9.01    Financial Statements and Exhibits.
(d) Exhibits.
Exhibit
NumberDescription
99.1
Press release issued August 4, 2025.
99.2
Slide presentation.
104Inline XBRL for the cover page of this Current Report on Form 8-K.




SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
CASTLE BIOSCIENCES, INC.
By:/s/ Frank Stokes
Frank Stokes
Chief Financial Officer
Date: August 4, 2025
 



FAQ

How many BFST shares are being sold under this Form 144?

The filing covers 5,164 common shares of Business First Bancshares.

What is the estimated value of the planned BFST share sale?

The aggregate market value stated is $119,186.15.

When is the anticipated sale date for the BFST shares?

The approximate sale date disclosed is August 4, 2025.

What percentage of BFST’s shares outstanding does this sale represent?

Only about 0.017 % of the 29,694,986 shares outstanding.

Which broker is handling the insider sale?

Morgan Stanley Smith Barney LLC, Executive Financial Services, New York.
Castle Biosciences

NASDAQ:CSTL

CSTL Rankings

CSTL Latest News

CSTL Latest SEC Filings

CSTL Stock Data

590.32M
28.02M
2.96%
93.21%
4.89%
Diagnostics & Research
Services-medical Laboratories
Link
United States
FRIENDSWOOD